|
|
Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?
Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Ace the Case: Older Adult with Therapy-Related AML
Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Ace the Case: Supporting Older Adults with AML
Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |
|